ArticleCureus2023

ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report.

Hirokazu Takayasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.